Prognostic impact of discordance between different risk assessment tools in early breast cancer (recurrence score, central grade, Ki67): Early outcome analysis from the prospective phase III WSG-PlanB trial

被引：2
|
作者：
Nitz, Ulrike [1 ,2 ]
Gluz, Oleg [1 ,2 ]
Kates, Ronald E. [1 ]
Hofmann, Daniel [1 ]
Kreipe, Hans H. [3 ]
Christgen, Matthias [3 ]
Shak, Steve [4 ]
Clemens, Michael [5 ]
Kraemer, Stefan
Aktas, Bahriye [6 ]
Kuemmel, Sherko [7 ]
Reimer, Toralf [8 ]
Kusche, Manfred [9 ]
Heyl, Volker [10 ]
Lorenz-Salehi, Fatemah [11 ]
Just, Marianne [12 ]
Liedtke, Cornelia [1 ,13 ]
Wuerstlein, Rachel [1 ,14 ]
Harbeck, Nadia [1 ,14 ]
机构：
[1] West German Study Grp, Dusseldorf, Germany
[2] Ev Hosp Bethesda, Breast Ctr Niederrhein, Monchengladbach, Germany
[3] Hannover Med Sch, Inst Pathol, Hannover, Germany
[4] Genom Hlth Inc, Redwood City, CA USA
[5] Breast Ctr, Mutterhaus Borromaerinnen, Trier, Germany
[6] Univ Clin Essen, Women Clin, Essen, Germany
[7] Clin Essen Mitte, Women Clin, Essen, Germany
[8] Clin Suedstadt, Rostock, Germany
[9] Marien Hosp Aachen, Women Clin, Aachen, Germany
[10] Asklepios Paulinen Clin, Wiesbaden, Germany
[11] Dr Horst Schmidt Clin, Women Clin, Wiesbaden, Germany
[12] Oncol Practice, Bielefeld, Germany
[13] Univ Clin Schleswig Holstein, Kiel, Germany
[14] LMU, Univ Clin Grosshadern, Breast Ctr, Munich, Germany
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.SABCS14-P4-11-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-11-01
引用
收藏
页数：2
相关论文
共 36 条
  • [11] Association of TILs with clinical parameters, recurrence score, and prognosis in patients with early HER2-negative breast cancer (BC) A translational analysis of the prospective WSG planB trial
    Liedtke, C.
    Gluz, O.
    Heinisch, F.
    Feuerhake, F.
    Kreipe, H. H.
    Clemens, M.
    Nuding, B.
    Kraemer, S.
    Reimer, T.
    Svedman, C.
    Shak, S.
    Nitz, U.
    Kates, R. E.
    Harbeck, N.
    Christgen, M.
    CANCER RESEARCH, 2016, 76
  • [12] Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial
    Kolberg-Liedtke, Cornelia
    Oleg, Gluz
    Fred, Heinisch
    Friedrich, Feuerhake
    Hans, Kreipe
    Michael, Clemens
    Benno, Nuding
    Wolfram, Malter
    Toralf, Reimer
    Rachel, Wuerstlein
    Monika, Graeser
    Steve, Shak
    Ulrike, Nitz
    Ronald, Kates
    Matthias, Christgen
    Nadia, Harbeck
    BREAST CANCER RESEARCH, 2020, 22 (01)
  • [13] Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression
    Nitz, U.
    Gluz, O.
    Huober, J.
    Kreipe, H. H.
    Kates, R. E.
    Hartmann, A.
    Erber, R.
    Scholz, M.
    Lisboa, B.
    Mohrmann, S.
    Moebus, V.
    Augustin, D.
    Hoffmann, G.
    Weiss, E.
    Boehmer, S.
    Kreienberg, R.
    Du Bois, A.
    Sattler, D.
    Thomssen, C.
    Kiechle, M.
    Jaenicke, F.
    Wallwiener, D.
    Harbeck, N.
    Kuhn, W.
    ANNALS OF ONCOLOGY, 2014, 25 (08) : 1551 - 1557
  • [14] Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)—a translational analysis of the prospective WSG PlanB trial
    Cornelia Kolberg-Liedtke
    Oleg Gluz
    Fred Heinisch
    Friedrich Feuerhake
    Hans Kreipe
    Michael Clemens
    Benno Nuding
    Wolfram Malter
    Toralf Reimer
    Rachel Wuerstlein
    Monika Graeser
    Steve Shak
    Ulrike Nitz
    Ronald Kates
    Matthias Christgen
    Nadia Harbeck
    Breast Cancer Research, 22
  • [15] PROSPECTIVE COMPARISON OF UPA/PAI-1, KI-67 BASED MOLECULAR CLASSIFICATION AND RECURRENCE SCORE IN HORMONE-RECEPTOR POSITIVE PRIMARY BREAST CANCER: PILOT PHASE OF THE RANDOMIZED WSG PLANB TRIAL
    Degenhardt, T.
    Gluz, O.
    Liedtke, C.
    Kreipe, H. H.
    Kates, R.
    Baehner, R.
    Bensman, E.
    Augustin, D.
    Nitz, U.
    Harbeck, N.
    ANNALS OF ONCOLOGY, 2011, 22 : 45 - 45
  • [16] Genomic markers but not molecular subtypes provide prognostic impact and predict anthracycline efficacy in early triple-negative breast cancer: Results from the prospective WSG PlanB trial
    Gluz, Oleg
    Liedtke, Cornelia
    Prat, Aleix
    Christgen, Matthias
    Gebauer, Daniel
    Kates, Ronald
    Pelz, Enrico
    Clemens, Michael
    Warm, Matthias
    Aktas, Bahriye
    Kuemmel, Sherko
    Pare, Laia
    Krabisch, Petra
    Kreipe, Hans Heinrich
    Wuerstlein, Rachel
    Nitz, Ulrike
    Harbeck, Nadia
    CANCER RESEARCH, 2018, 78 (04)
  • [17] Prospective comparison of Recurrence Score, uPA/PAI-1, central grade and molecular subtyping in early breast cancer: first results from the WSG-Plan B trial (interim analysis)
    Wuerstlein, R.
    Gluz, O.
    Kreipe, H.
    Kates, R.
    Degenhardt, T.
    Liedtke, C.
    Shak, S.
    Nitz, U.
    Harbeck, N.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S33 - S34
  • [18] Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2-early breast cancer (EBC) patients with 1-3 involved lymph nodes
    Gluz, O.
    Nitz, U.
    Christgen, M.
    Kates, R.
    Clemens, M.
    Nuding, B.
    Shak, S.
    Wuerstlein, R.
    Kreipe, H.
    Harbeck, N.
    BREAST, 2017, 32 : S93 - S93
  • [19] Clinical impact of risk classification by central/local grade or luminal-like subtype vs. Oncotype DX®: First prospective survival results from the WSG phase III planB trial
    Gluz, O.
    Nitz, U.
    Kreipe, H. H.
    Christgen, M.
    Kates, R. E.
    Hofmann, D.
    Shak, S.
    Clemens, M.
    Kraemer, S.
    Aktas, B.
    Kuemmel, S.
    Reimer, T.
    Kusche, M.
    Heyl, V.
    Lorenz-Salehi, F.
    Just, M.
    Liedtke, C.
    Wuerstlein, R.
    Harbeck, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S311 - S311
  • [20] West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment
    Gluz, Oleg
    Nitz, Ulrike A.
    Christgen, Matthias
    Kates, Ronald E.
    Shak, Steven
    Clemens, Michael
    Kraemer, Stefan
    Aktas, Bahriye
    Kuemmel, Sherko
    Reimer, Toralf
    Kusche, Manfred
    Heyl, Volker
    Lorenz-Salehi, Fatemeh
    Just, Marianne
    Hofmann, Daniel
    Degenhardt, Tom
    Liedtke, Cornelia
    Svedman, Christer
    Wuerstlein, Rachel
    Kreipe, Hans H.
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (20) : 2341 - U66
1234